CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] The present patent application claims the priority benefit of U.S. provisional patent application number 62/666,499 filed May 3, 2018, the disdosure of which is incorporated by reference herein.

BACKGROUND OF THE INVENTION

1. Field Of The Disclosure

[0002] The present disdosure is generally related to a method for extrading

pharmacologically adive compounds. More particularly, the present disdosure relates to extradion of Delta-9-Tetrahydrocannabinol (THC) and related compounds from cannabis biomass.

2. Description of the Related Art

[0003] Cannabis is a genus belonging to the family of cannabaceae. Three common spedes indude Cannabis sativa, Cannabis indica, and Cannabis ruderalis. The genus has been indigenous to Central Asia and the Indian subcontinent. Cannabis has a long history being used for medidnal, therapeutic, and recreational purposes. The importance of cannabis in therapeutics is emphasized by the ever-increasing number of research publication related to the new indications for cannabis. For example, pharmaceutical research companies are presently developing new natural cannabinoid formulations and delivery systems to meet various regulatory requirements. Cannabis is known, for example, to be capable of relieving nausea (such as that accompanying chemotherapy), pain, vomiting, spastidty in multiple sclerosis, and increase hunger in anorexia.

[0004] The term "biomass" encompasses organic matter derived from plants or

microorganisms. The term cannabis or "cannabis biomass" encompasses the Cannabis sativa plant and also variants thereof, including subspecies sativa, indica and ruderalis, cannabis cultivars, and cannabis chemovars (varieties charaderised by chemical composition), which naturally contain different amounts of the individual cannabinoids, and also plants which are the result of genetic crosses. The term "cannabis biomass" is to be interpreted accordingly as encompassing plant material derived from one or more cannabis plants.

[0005] Cannabinoids are unique to cannabis genus. Such cannabinoids are generally produced by glandular trichomes that occur on most aerial surfaces of the plant. The cannabinoids are biosynthesized in the plant in acidic forms known as addic cannabinoids. The acidic cannabinoids may be slowly decarboxylated during drying of harvested plant material. Decarboxylation may be hastened by heating the cannabis biomass, such as when the cannabis biomass is smoked or vaporized.

[0006] In particular, cannabis biomass contains a unique class of cannabinoids, which may also be known as terpeno-phenolic compounds or phytocannabinoids, which have been extensively studied since the discovery of the chemical structure of tetrahydrocannabinol (Delta- 9-THC), commonly known as THC. Over 113 phytocannabinoids have been identified. The principle cannabinoids present in cannabis are the Delta-9-tetrahydrocannabinolic add (Delta-9- THCA) and cannabidiolic acid (CBDA). The Delta-9-THCA does not have its own psychoadive properties as is, but may be decarboxylated to Delta-9-tetrahydrocannabinol (Delta-9-THC), which is the most potent psychoadive cannabinoid among known cannabinoids. The neutral form of CBDA is cannabidiol (CBD), which is a major cannabinoid substituent in hemp cannabis. CBD is non-psychoactive and is widely known to have therapeutic potential for a variety of medical conditions. The proportion of cannabinoids in the plant may vary from spedes to spedes, as well as vary within the same species at different times and seasons.

Furthermore, the proportion of cannabinoids in a plant may further depend upon soil, climate, and harvesting methods. Thus, based on the proportion of the cannabinoids present in a plant variety, the psychoadive and medicinal effects obtained from different plant varieties may vary.

[0007] Depending upon the psychoadive and medidnal effeds obtained from different varieties of the cannabis plant or the different methods of cultivation for cannabis, a spedfic variety of cannabis may be considered more effective or potent than others ( e.g ., in providing the desired physiological effed at a desired level in an individual). Similarly, some spedfic combinations of pharmacologically adive compounds in a cannabis variety may be more desirable in comparison to other varieties. When preparing cannabis plant extrads, the retention of the full mix of cannabinoids present in the original plant may be desirable for some varieties, while other varieties may be preferred in altered form due to the variances in the specific cannabinoid composition and concentrations. Such variance is further exacerbated by the presence of certain terpenoid or phenolic compounds, which may have pharmacological activity of their own and which may be desired at different concentrations in different combinations.

The "entourage effect" generally refers to an endogenous cannabinoid molecular regulation route by which different combinations of active compounds and inactive compounds may act in concert to produce a spectrum of different biological effects. In some instances, an entourage effect may result in whole plant synergy treatments having different effects than the isolated active compounds therein.

[0008] Historical delivery methods have involved smoking ( e.g ., combusting) the dried cannabis plant material. Smoking results, however, in adverse effects on the respiratory system via the production of potentially toxic substances. In addition, smoking is an inefficient mechanism that delivers a variable mixture of active and inactive substances, many of which may be undesirable. Alternative delivery methods such as ingesting typically require extracts of the cannabis biomass (also known as cannabis concentrates or cannabis oils). Often, cannabis extracts are formulated using any convenient pharmacologically acceptable diluents, carriers or exdpients to produce a composition. Raw cannabis biomass may also be more susceptible to possible biological contaminants such as fungi and bacteria than extracts.

[0009] Thus, there is a need in the art for improved systems and methods of preparing a composition containing cannabinoids in proportions desired by an end-user, such as may be prepared in accordance with plant profiles to mimic specific cultivars and their respective natural and historical tastes and biological effects, including entourage effects. Such methods may further allow for customization of profiles, which may or may not be based on existing plant profiles and combinations thereof.

SUMMARY OF THE CLAIMED INVENTION

[0010] Embodiments of the present invention include systems and methods for preparing profile-based blends. A blend profile may be received at a blending apparatus. Such blend profile may include a plurality of components each associated with a specified concentration. A sample of a biomass may be analysed to identify that the biomass includes the plurality of components, albeit at different concentration(s) than in the blend profile. The plurality of components may be extracted from a biomass slurry resulting from the biomass and a solvent. One or more of the extracted components may be isolated and held in separate chambers. A blend may be created by titrating one or more of the isolated components in accordance with the respective specified concentration in the received blend profile. In some embodiments, the blend profile corresponds to an analysis of a biomass sample ( e.g ., of a specified plant or cultivar).

BRIEF DESCRIPTION OF THE DRAWINGS

[0011] FIG. 1 is a flowchart illustrating an exemplary method for preparing blends that mimics a plant profile.

[0012] FIG. 2 is a block diagram representation of an exemplary system for preparing blends that mimic a plant profile.

[0013] FIG. 3 is a diagram illustrating exemplary components of a formulation that may be prepared to mimic a plant profile.

DETAILED DESCRIPTION

[0014] Embodiments of the present invention include systems and methods for preparing profile-based blends. A blend profile may be received at a blending apparatus. Such blend profile may include a plurality of components each associated with a specified concentration. A sample of a biomass may be analysed to identify that the biomass includes the plurality of components, albeit at different concentration(s) than in the blend profile. The plurality of components may be extracted from a biomass slurry resulting from the biomass and a solvent. One or more of the extracted components may be isolated and held in separate chambers. A blend may be created by titrating one or more of the isolated components in accordance with the respective specified concentration in the received blend profile.

[0015] In some embodiments, the blend profile corresponds to a biomass sample ( e.g ., of a specified plant or cultivar). Such implementations therefore allow for various compositions to be prepared from a cannabis biomass in which pharmacologically active compounds may be present in different concentration than that desired. Depending on the specific blend profile desired, one or more compounds may be extracted from the biomass, isolated, and formulated in a predetermined concentration or proportion. Such components may include such pharmacologically active compounds as cannabinoids, terpenes, terpenoids, and flavonoids, as well as a variety of different inactive compounds found in the provided biomass or from other sources. For example, different plants may be used as raw biomass to extract such inactive compounds, which may thereafter be isolated and titrated into a final blend in a manner similar to that used for active compounds. Such inactive compounds may be included to enhance, promote, or complement certain therapeutic effects (e.g., anti-inflammatory,

antiseptic/antibacterial/antifungal, pain relief, stress relief).

[0016] The blend profile may, for example, correspond to a predefined composition of a specific cannabis plant varietal or cultivar. As such, mimicry of a specific composition (and its biological effects) may be achieved. Specific cannabis plant profiles may be recreated by combining quantities of various isolated cannabinoids, terpenoids, and flavonoids to form a blend with or without selected additive(s), diluent(s), carrier fluid(s) or exdpient(s). Each plant profile may refer to different active components, different inactive components, and different proportions thereof present in the corresponding plant. For example, each cultivar may have a unique proportion of cannabinoids and terpenes, and not all cannabinoids may be present in detectable amounts in a single plant variety.

[0017] In some embodiments, therefore, different plant profiles and combinations thereof may provide the basis for a desired blend profile. In addition, a blend profile may further be customized based on user preference ( e.g ., specifications regarding favored or disfavored plants/cultivars, active and inactive components, solvents, carrier fluids, types of biological effects, other sensory effects, flavors, aromas). For example, recreating a blend profile with a given biomass may involve increasing (relative to the initial biomass) a concentration of one or more specified terpenes to impart a desired aroma and/or flavor to the final blend product. The terpenes may be obtained from the initial cannabis biomass or may also be obtained from other non-cannabis biomass.

[0018] In another embodiment, the present invention provides a method of preparing the composition. The method includes extracting and isolating various cannabinoids or groups of cannabinoids from one or more cultivars of cannabis. Each cultivar of cannabis may have a different plant profile (e.g., ratio and quantities of specific cannabinoids). Many different cultivars may be analyzed to generate a respective specific plant profile, which may represent a specific set of medicinal and/or recreational effects to different users. Depending on the specific components specified (and/or disfavored) in a given blend profile, such components may be isolated from a given biomass. As used herein, an isolated component may be inclusive of specific, pure compounds, as well as specific arrays of compounds, that may be used to achieve a desired composition. An isolate may therefore include a single cannabinoid or a group of cannabinoids, which may then be titrated into a formulation that mimics the plant profile of a known cultivar. This may allow the formulation to provide the same "entourage effect" of a specific plant or cultivar.

[0019] In some embodiments, the blend profile (and resulting formulation) may be further customized so to include quantities or proportions of cannabinoids that may not be found in any known cultivar profiles, which may provide (and/or avoid) effects that the natural plant profile could not produce. Whereas plant profiles may allow for formulated blends that may mimic known natural biological and sensory effects of the corresponding plants and cultivars, customized blend profiles may further enhance and/or diminish a selection of such effects. As such, the resulting formulation created by such customized blend profiles may provide for a set of effects that may not be available at the same level of efficacy or potency from natural resources or cultivars, at least not without requiring impractically high levels of natural and financial resources.

[0020] The process for preparing the composition may now be explained with reference to FIG. 1 and FIG. 2. FIG. 1 is a flowchart illustrating an exemplary method for preparing blends that mimics a plant profile, and FIG. 2 is a block diagram representation of an exemplary system for preparing blends that mimic a plant profile. One skilled in the art will appreciate that, for this and other processes and methods disclosed herein, the functions performed in the processes and methods may be implemented in differing order. Furthermore, the outlined steps and operations are only provided as examples, and some of the steps and operations may be optional, combined into fewer steps and operations, or expanded into additional steps and operations without detracting from the essence of the disclosed embodiments.

[0021] In step 102, a blend profile may be received at controller 201. Such a blend profile may be provided ( e.g ., transferred or retrieved from database or inputted) in full or created based on inputs regarding specified components and respective concentrations thereof. In some embodiments, a blend profile may be generated by sampling chamber 204 (based on a sample that includes one or more plants or cultivars thereof). In some embodiments, controller 201 may further generate a blend profile based on a set of desired biological and/or sensory effects. The blend profile may further be generated by controller 201 based on one or more user preferences. In addition to specifying a set of active components (e.g., cannabinoids, terpenoids, and flavonoids) and concentrations thereof, the received blend profile may further specify certain favored or disfavored solvents, carrier fluids, and flavouring or aromatic compounds.

[0022] In step 104, a biomass sample is analyzed to identify whether its constituent components correspond to those of the received blend profile. For example, a sample of raw cannabis plant biomass may be analyzed to determine cannabinoid content, and a specific plant profile (of the specific cannabinoids, terpenoids, flavonoids, etc., and concentrations thereof) may be generated. Cannabindoid analysis may be performed, for example, using an Ultra Fligh Performance Liquid Chromatography coupled with Mass Spectrometry (UPLC-MS) detection technique. Further, the terpenoid content of the raw biomass may be determined using a Gas Chromatography-Mass Spectrometry Detection (GC-MS). Such sampling techniques may help in determining the active compound content and the plant profile of the raw biomass (i.e., THCA, THC, CBDA, CBD, and total cannabinoids present in the raw biomass). Such sampling by sampling chamber 204 allows for determination of whether the components specified by the received blend profile are present in a particular biomass and to what respective concentrations. Such information may be used by controller 201 to set certain parameters in the extraction process, so as to achieve extraction and isolation of the desired components at the desired concentrations.

[0023] Table 1 (provided below) illustrates exemplary compositions from five different samples of cannabis biomass (each associated with different cannabis cultivars). In particular, Table 1 illustrates test data related to various cannabis biomass samples collected from different cannabis cultivars (strains), locations, and on different dates. In one case, five cultivars (cultivars A to D) from Location 1 were analyzed by UHPLC and found to have wide variability in cannabinoid profiles (e.g. THCA, THC, CBDA, CBD and total cannabinoids content). In other cases, different cultivars from different locations also were found to have variability in cannabinoid profile. In one case, Cultivar G from Location 4 was determined to have very low concentrations of cannabinoids. In another case, identical cultivars I from location 4 were analyzed by UHPLC and found to have variability in cannabinoid profile based on the date of harvest. In a preferred embodiment, the conditions used for the method of extracting pharmacologically active ingredients from cannabis biomass as described herein may be adjusted and controlled based on the results of the raw biomass sampling and analysis so as to increase purity and yield of cannabis extract.

Table 1

[0024] A spedfic cultivar (assodated with a spedfic biomass sample) may therefore be seleded and its assodated biomass provided to raw biomass holding chamber 202. In some embodiments, such biomass may be provided in the form of dried, ground, non-decarboxylated parts of cannabis plants, induding flowers, buds, and leaves. The buds may contain a maximum amount of cannabinoids in comparison to other parts of the plant, but any suitable part of the cannabis biomass ( e.g ., that contains the cannabinoids specified by the received blend profile) can be used or induded in the raw biomass that is provided to raw biomass holding chamber 202. In some embodiments, the raw biomass may further be heated to approximately 125° C for approximately 45 minutes to decarboxylate the cannabinoid carboxylic acids into neutral cannabinoid forms. The mass of decarboxylated cannabis following such treatment may get reduced (e.g., 11.7% weight loss). Depending on the specific blend profile received, the raw biomass may preferably be dried, non-decarboxylated cannabis biomass. In another embodiment, the received blend profile may prefer that raw biomass be fresh, non-dried, non- decarboxylated cannabis biomass.

[0025] In step 106, the raw biomass provided to raw biomass holding chamber 202 may be processed to form a slurry. Initially, preparing the raw biomass may include pulverization to a predetermined size for extraction. For example, the biomass may be pulverized to a size of 0.5 - 10 mm in biomass preparation chamber 206, which may include suitable apparatus for pulverizing the biomass, such as a ball mill or a knife mill. In some embodiment, average particle size of the raw biomass may lie between 0.5 - 10 mm. The prepared biomass may then be provided to and held in a prepared biomass holding chamber208.

[0026] The prepared biomass may thereafter be transferred from the prepared biomass holding chamber 208 to the slurry formation chamber 210 for combination with a suitable solvent that is supplied from solvent holding chamber 212. The solvent holding chamber 212 may be a tank or canister of suitable volume. The solvent may be pumped from the solvent holding chamber 212 to the slurry formation chamber 210 using a suitable pumping mechanism known in the art for transporting fluids.

[0027] One or more suitable solvent(s) may be selected based on the received blend profile, which may indicate specific favored solvent(s) or favored solvent properties ( e.g ., dilectric). Such selected solvent may be, for example, a Medium Chain Triglyceride (MCT) (e.g., coconut oil) or other edible and food-grade solvent or emulsifier used to standardize active compounds in pharmaceutical, nutraceutical, functional, food, or cosmetic formulations. Such solvent may therefore further be pharmaceutical-grade and/or cosmetics-grade. Further, the solvent may be a polyunsaturated fatty add (PUFA), corn oil, safflower oil, borage oil, flax oil, canola oil, cottonseed oil, soybean oil, olive oil, sunflower oil, coconut oil, palm oil, monoglycerides, diglycerides, triglycerides, medium chain or long chain triglycerides, ledthin, limonene, essential oils of spices, herbs or other plants, fish oil, glycerol, glycols, or any other, or mixtures thereof. The solvent may also be seleded from alcohols (e.g., ethanol, isopropanol), alkanes (e.g., pentane), and ketones (e.g., acetone, butanone), and binary mixtures of each, or a combination thereof.

[0028] The specific solvent(s) and the ratio of solvent-to-biomass may be adjusted based on the spedfic combinations being used, as well as the specific blend specified by the blend profile. In an exemplary embodiment, the solvent may be used in a predefined ratio of 10 litres of solvent to 1 kg of cannabis biomass. The solvent-to-raw biomass ratio may be maintained at approximately 5-10 1/kg to ease the pumping operation of the slurry. In an embodiment, the solvent-to-raw biomass ratio may be maintained as low as possible so as to maximize the concentration of the pharmacologically active compounds that are extracted.

[0029] Thereafter in step 108, the slurry may be transferred from the slurry formation chamber 210 to an extraction chamber 214 where such slurry is subject to heat. The slurry may be transported using a set of mechanical conveyors ( e.g ., slurry pump, screw conveyor or worm gear). In the extraction chamber 214, the slurry may be subjected to a thermal process, such as provided by a microwave generator 216. It may be understood that the selected solvent(s) may require a specific temperature to facilitate efficient transportation through the set of mechanical conveyors. For example, the solvent {e.g., MCT) may be heated with thermal energy {e.g., from microwave generator 216) to a temperature that meets or exceeds the solvent's melting point. In one case, the slurry may be transported into an extraction chamber 214 through a tube.

Extraction chamber 214 may include a portion that is microwave transparent, which may allow microwaves {e.g., generated using a magnetron of microwave generator 216) to pass through and heat the slurry inside the extraction chamber 214. The slurry may be heated within the extraction chamber 214 to a certain temperature by exposing the slurry to the microwave to a predefined time with a predefined microwave energy density range. In a preferred embodiment, the slurry may be heated to a temperature range of 20 - 75° C with a contact time of 1 - 30 minutes, and microwave energy density range of 0.1 - 10 kW/kg. Such heating may facilitate the extraction of various (pharmacologically active) compounds from the prepared biomass into the solvent. In some embodiments, however, due care may be taken to keep the operating temperatures in the thermal process low as to avoid the decarboxylation of acidic cannabinoids.

[0030] Post extraction, the slurry— now including a spent biomass, solvent(s), and extracted components— may be transported to separation chamber 218, wherein the slurry is subject to filtration and separation in step 110. Once separated from the extracted compounds, the spent biomass and the solvent(s) may be transferred into spent biomass storage chamber 118 and solvent recovery chamber 122, respectively. The now-spent biomass may be separated from the solvent(s) and now-extracted compounds using one or more of several methods, such as filtration, centrifugation, and other similar processes. In one embodiment, the separation process may include use of a filter press. [0031] The spent biomass, now be stored in a spent biomass storage chamber 220, may be sampled and analysed in a sampling chamber 120 to determine whether any significant amount of active compounds remain unextracted. Post sampling and analysis of the spent biomass, waste spent biomass may be incinerated, mixed with a deactivating agent ( e.g ., clay), or otherwise disposed of.

[0032] Some blend profiles may involve use of a solvent that may be incorporated into the final blend. Such solvent therefore do not need to be removed (entirely) from the extract/solvent mixture. Some embodiments, however, may use solvent(s) that are not suitable for inclusion in a final blend product. In such instances, an extract/solvent mixture may first be separated from the spent biomass, and the solvent may further be separated from the extract/solvent mixture and recovered by a solvent recovery chamber 222. As a result, a desolvenized extract may be obtained. Such separation may be achieved by way of any combination of vacuum distillation, vacuum concentration, other distillation or evaporation-based process, or any similar method known in the art. In vacuum distillation, the solvent may be evaporated out of the miscella using distillation under reduced pressure. The solution may be subjected to vacuum, which may enable distillation process to occur at a lower temperature. This is because, under vacuum, boiling point of the solvent gets lowered. Such low temperature may also be advantageous to temperature sensitive components in the miscella. In some embodiments, vacuum distillation method may further minimize decarboxylation of the acidic cannabinoids due to exposure to high temperatures. In preferred embodiments, the separation may be effected by thin-film evaporation methods, for example wiped-film evaporation. Recovered solvent may be used in subsequent extraction process.

[0033] In step 112, the extracted components (e.g., pharmacologically active compounds) may be isolated. In some embodiments, the extracted components— now separated from the spent biomass and solvent(s)— may be sampled and analyzed in the sampling chamber 120 to identify its specific components (e.g., Delta-9-THC, Delta-9-THCA, CBDA, CBD, other cannabinoids, terpenes, or other medicinal value compounds). In a preferred embodiment, analysis of the extracted components may be done to determine cannabinoid, terpenoid, flavonoic, etc., content. The analysis may be performed using an Ultra High Performance Liquid Chromatography coupled with Mass Spectrometry detection (UPLC-MS) and/or Gas

Chromatography-Mass Spectrometry Detection (GC-MS). Such sampling by sampling chamber 204 may allow for identification of whether certain components have been extracted in amounts sufficient to create the desired blend.

[0034] In some embodiments, certain pharmacologically active compounds, such as Delta-9- THC, may be extracted from one biomass having high concentrations thereof, while other components, such as terpenes and flavonoids, may be isolated from different biomass having high proportions of the desired terpenes and/or flavonoids. The different pharmacologically active compounds may thereafter be isolated from the extract and transported to distinct actives isolation chamber(s) 224. The actives isolation chamber(s) 224 may have suitable apparatuses for effecting isolation of active compounds, such as column chromatography, fractional distillation, or short-path distillation.

[0035] The chromatography technique has many subtypes that may be specifically used to purify or isolate different cannabinoids. For example, bio-affinity chromatography is a type of chromatography technique that relies on the property of biologically active substances to form stable, specific, and reversible complexes. Formation of these complexes may involve the participation of common molecular forces, such as the Van der Waals interaction, electrostatic interaction, dipole-dipole interaction, hydrophobic interaction, and hydrogen bond. An efficient, bispecific bond may be formed by a simultaneous and concerted action of several of these forces in the complementary binding sites. Other types of chromatography that may be used include partition chromatography, normal-phase chromatography, displacement chromatography, reversed-phase chromatography, size-exclusion chromatography, ion-exchange

chromatography, aqueous normal-phase chromatography and simulated moving bed chromatography.

[0036] Post-isolation in step 114, the pharmacologically active compounds may be formulated into a created blend in accordance with the receivd blend profile. To prepare the composition according to the blend profile received in step 102, the isolated components (e.g. pharmacologically active compounds) may be titrated in accordance with the

concentrations specified by the blend profile. The active compounds held by actives isolation chamber(s) 224 may be transported to the formulation chamber 226, and the final product blend may be stored in the product storage chamber 228. The relative concentrations of each cannabinoid, terpene, etc., within the final blend product may also be sampled and tested by sampling chamber 204 to ensure conformity to the components and respective concentrations spedfied by the received blend profile. Samples obtained at the formulation chamber 226 and the produd storage chamber 228 may be analyzed by sampling chamber 204 using suitable analytical methods known in the art for analyzing natural products. For example, the analysis of cannabinoids amount, and cannabinoids profiling may be performed using ultra high- performance liquid chromatography coupled with mass spedrometry detedion (UPLC-MS). In addition, the samples may be analyzed for terpene profile using gas chromatography coupled with mass spedrometry (GC-MS).

[0037] As such, the final blend product may have a profile corresponding to a known plant profile or may be a unique blend profile that has been customized for a spedfic purpose ( e.g ., medidnal, recreational, experimental, etc.) for a spedfic individual having certain preferences and medical or physiological conditions. The titration process may result, for example, in a final formulation blend of spedfic cannabinoids and terpenes. The formulation blend may further incorporate different additives, diluents, carrier fluids, exdpients, flavouring agents, and aromatic compounds for spedfic modes of delivery (e.g., formulated with a medium chain triglyceride for use in a food product). In some embodiments, the final blend produd may be formulated in any of known dosage forms (e.g., capsules).

[0038] FIG. 3 is a diagram illustrating exemplary components of a formulation 300 that may be prepared to mimic a plant profile. As illustrated, specified cannabinoids may be titrated in combination with different terpenes to create a blend in accordance with a received blend profile. Spedfically, the titrated blend includes A% of Cannabinoid 1, B% of Cannabinoid 2, C% of Cannabinoid N, X% of Terpene 1, Y% of Terpene 2, and Z% of Terpene N.

[0039] Examples of cannabinoids that may be isolated from cannabis plant may indude Delta-9-TlTCA (Delta-9-Tetrahydrocannabinolic acid), CBD (Cannabidiol), BDA (Cannabidiolic Add) , CBN (Cannabinol), CBG (Cannabigerol), CBC (Cannabichromene), CBL (Cannabicydol), CBV (Cannabivarin), T1TCV (Tetrahydrocannabivarin), CBDV (Cannabidivarin), CBCV

(Cannabichromevarin), CBGV (Cannabigerovarin), CBGM (Cannabigerol Monomethyl Ether), CBE (Cannabielsoin), CBT (Cannabidtran). Examples of terpenes that may be isolated from a cannabis plant or any other plant may indude a Pinene, Linalool, Myrcene, Limonene, Odmene, Terpinolene, Terpineol, Valencene, b Caryophyllene, Geraniol, Flumulene, Phellandrene,

Carene, Terpinene, Fenchol, Borneol, Bisabolol, Phytol, Camphene, Sabinene, Camphor, and Isoborneol. [0040] According to present invention, cannabinoid blends may be created that treat specific conditions based on known uses of specific cannabinoids and/or terpenes. A

formulation of this type may be more successful at treating specific conditions compared to any whole plant. Exemplary embodiments of the prepared formulations include topical formulations for pain relief and anti-fungal infections of the skin.

[0041] The foregoing detailed description of the technology has been presented for purposes of illustration and description. It is not intended to be exhaustive or to limit the technology to the precise form disclosed. Many modifications and variations are possible in light of the above teaching. The described embodiments were chosen in order to best explain the principles of the technology, its practical application, and to enable others skilled in the art to utilize the technology in various embodiments and with various modifications as are suited to the particular use contemplated. It is intended that the scope of the technology be defined by the claim.